{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:30:08Z","timestamp":1773145808195,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"},{"start":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T00:00:00Z","timestamp":1281398400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/2.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9640-y","type":"journal-article","created":{"date-parts":[[2010,8,9]],"date-time":"2010-08-09T21:46:52Z","timestamp":1281390412000},"page":"1527-1529","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib"],"prefix":"10.1007","volume":"28","author":[{"given":"Ana M.","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle S.","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Motzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,8,10]]},"reference":[{"key":"9640_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125\u201334.","journal-title":"N Engl J Med"},{"key":"9640_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115\u201324.","journal-title":"N Engl J Med"},{"key":"9640_CR3","doi-asserted-by":"crossref","unstructured":"Sternberg CN, et al. A randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC). J Clin Oncol. 2009;27:15s (suppl; abstr 5021).","DOI":"10.1200\/jco.2009.27.15_suppl.5021"},{"key":"9640_CR4","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271\u20132281.","journal-title":"N Engl J Med"},{"key":"9640_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008;372:449\u201356.","journal-title":"Lancet"},{"key":"9640_CR6","doi-asserted-by":"publisher","unstructured":"Motzer RJ, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer. 2010;116(118). doi:10.1002\/cncr.25219.","DOI":"10.1002\/cncr.25219"},{"key":"9640_CR7","doi-asserted-by":"crossref","first-page":"618","DOI":"10.6004\/jnccn.2009.0043","volume":"7","author":"RJ Motzer","year":"2009","unstructured":"Motzer RJ, et al. NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw. 2009;7:618\u201330.","journal-title":"J Natl Compr Canc Netw."},{"key":"9640_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.ejca.2008.12.010","volume":"45","author":"TM de Reijke","year":"2009","unstructured":"de Reijke TM, et al. EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer. 2009;45:765\u201373.","journal-title":"Eur J Cancer"},{"key":"9640_CR9","unstructured":"Hutson TE, et al. Everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the RECORD-1 study. Presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5\u20137, 2010, San Francisco, CA. Abstract and Poster 362."},{"key":"9640_CR10","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1002\/cncr.24280","volume":"115","author":"RJ Amato","year":"2009","unstructured":"Amato RJ, et al. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115:2438\u201346.","journal-title":"Cancer."},{"key":"9640_CR11","doi-asserted-by":"publisher","unstructured":"Mackenzie MJ, et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma. Ann Oncol. doi:10.1093\/annonc\/mdq320. http:\/\/annonc.oxfordjournals.org\/content\/early\/2010\/06\/30\/annonc.mdq320.full.pdf+html.","DOI":"10.1093\/annonc\/mdq320"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-010-9640-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s12032-010-9640-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9640-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T21:13:13Z","timestamp":1630444393000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-010-9640-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,10]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9640"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9640-y","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,10]]},"assertion":[{"value":"18 June 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2010","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}